From Risk to Resilience: Personalizing IVF for PCOS - Reflections from ALIVE Issue 12
The evolving landscape of PCOS management
Polycystic ovary syndrome (PCOS) remains one of the most challenging conditions in reproductive endocrinology. As clinicians, we continue to balance stimulation efficacy with patient safety, especially when managing the risk of ovarian hyperstimulation syndrome (OHSS).
Insights from the latest ALIVE issue
In ALIVE Newsletter Issue 12, we explore the transition from traditional hCG triggering to GnRH agonist protocols, emphasizing:
- • Reduction of OHSS without compromising oocyte quality or pregnancy rates
- • The rationale for individualized luteal phase support (LPS)
- • Evidence supporting the freeze-all approach for high responders
- • The framework of an OHSS-free clinic through cycle segmentation
The issue integrates findings from recent randomized trials and updated ESHRE (2025) and ASRM (2024) recommendations—affirming that personalized stimulation and luteal strategies are now standard of care in PCOS-related IVF.
Moving forward
The conversation around PCOS is shifting—from managing complications to engineering safety through personalization. As reproductive specialists, our challenge is to integrate this evidence into daily practice and ensure every patient benefits from these advances.
🩺 Editor’s note: ALIVE continues to serve as a collaborative platform for ART professionals to exchange clinical wisdom and shape the next decade of reproductive innovatio